Approaching insulinoma: An updated review of the literature
PDF (Español (España))

Keywords

Insulinoma
pancreas
hypoglycemia
molecular biology
physiopathology
diagnosis
neoplasm staging
therapeutics
gastro-enteropancreatic neuroendocrine tumor

How to Cite

Castro Gomez, K. G., Contreras Romero, J. A., Afanador Jaimes, D. V., Álvarez Herrera, L. V., Gaitán Díaz, N. L., & Saavedra López, H. F. (2024). Approaching insulinoma: An updated review of the literature. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 11(1). https://doi.org/10.53853/encr.11.1.822

Abstract

Background: Insulinoma originates in the ?-cells of the pancreatic islets, in which insulin release is autonomous, avoiding counter-regulatory mechanisms. There are several proposed pathophysiological mechanisms, based on the presence of germinal or somatic pathogenic variants.

Objective: To provide information on the etiopathogenesis, genetics, epidemiology, clinic, diagnosis, staging, localization, treatment, and prognosis of insulinoma.

Methodology: Literature review in the PubMed database, Google Scholar and gray literature using the MeSH terms: “insulinoma”, “physiopathology”, “epidemiology“, “signs and symptoms”, “diagnosis”, “therapeutics”, “prognosis”, “gastro-enteropancreatic neuroendocrine tumor” and by review of bibliographical references list (in "snowball") of the selected studies.

Results: Insulinoma is the most common pancreatic neuroendocrine tumor with a nonspecific clinical presentation, which should be considered in the presence of adrenergic and neuroglycopenic symptoms, for which there is a range of diagnostic tools that should be used in a complementary approach given their limited sensitivity, and treatment should be oriented according to the characterization and staging of the tumor.

Conclusions: The diagnosis of insulinoma is delayed for several years due to its nonspecific clinical features, despite its mostly benign behavior, it is associated with great morbidity.

https://doi.org/10.53853/encr.11.1.822
PDF (Español (España))

References

Ekanayake AB, Stubbs H, Broutin D, Karasik O, Kinaan M. Not Just an Accident: A Case of Insulinoma. Cureus. 2023 Nov 8;15(11):e48514. 10.7759/cureus.48514. https://www.cureus.com/articles/176269-not-just-an-accident-a-case-of-insulinoma#!/

Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6(2):229-237. https://doi.org/10.2217/fon.09.165

Papadopoulos N, Hruban RH. Molecular genetics of neuroendocrine tumors. En Beger HG, Warshaw AL, Hruban RH, Lerch MM, et al. The Pancreas: an integrated textbook of basic science, medicine, and surgery; 2018. p. p. 937-946. https://doi.org/10.1002/9781119188421.ch123

Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, et al. The north american neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(7):8638-81. https://doi.org/10.1097/MPA.0000000000001597

Medina-Zamora P, Lucio-Figueroa JO. Insulinoma: revisión actual de manejo y tratamiento. Rev Med MD. 2015;6.7(2):83-90. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=63611

AlJadir SJ. Insulinoma: literature’s review (part 1). Endocrinol Metab Int J. 2015;2(3):112-122. https://doi.org/10.15406/emij.2015.02.00025

Minn AH, Kayton M, Lorang D, Hoffmann SC, et al. Insulinomas and expression of an insulin splice variant. Lancet. 2004;363(9406):363-367. https://doi.org/10.1016/S0140-6736(04)15438-X

Wiesli P, Perren A, Saremaslani P, Pfammatter T, et al. Abnormalities of proinsulin processing in functioning insulinomas: clinical implications. Clin Endocrinol (Oxf). 2004;61(4):424-430. https://doi.org/10.1111/j.1365-2265.2004.02095.x

Halperin Rabinovich I. Insulinoma. Endocrinol y Nutr. 2007;54(1):15-20. https://doi.org/10.1016/S1575-0922(07)71514-0

Irshad K, Jyotsna VP, Agarwal S, Chosdol K, et al. T372R mutation status in Yin Yang 1 gene in insulinoma patients. Horm Metab Res. 2017;49(6):452-456. https://doi.org/10.1055/s-0043-107244

Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, et al. Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas. J Clin Endocrinol Metab. 2015;100(5):E776-E782. https://doi.org/10.1210/jc.2015-1100

Chen Q, Wang W-J, Jia Y-X, Yuan H, et al. Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review. Cell Biosci. 2021;11(1):86. https://doi.org/10.1186/s13578-021-00602-8

Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25(8):1125-1142. https://doi.org/10.1038/sj.onc.1209080

Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021;17(4):207-224. https://doi.org/10.1038/s41574-021-00468-3

Taye A, Libutti S. Diagnosis and management of insulinoma: current best practice and ongoing developments. Res Reports Endocr Disord. 2015;2015(5):125-133. https://doi.org/10.2147/RRED.S86565

Fontanie?re S, Tost J, Wierinckx A, Lachuer J, et al. Gene expression profiling in insulinomas of Men1 ?-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic ?-cell tumorigenesis. Endocr Relat Cancer. 2006;13(4):1223-1236. https://doi.org/10.1677/erc.1.01294

Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer. 2017;24(10):T195-T1208. https://doi.org/10.1530/ERC-17-0243

Giannis D, Moris D, Karachaliou GS, Tsilimigras D, Karaolanis G, Papalampros A, et al. Insulinomas: from diagnosis to treatment. A review of the literature. J BUON [Internet]. 2020;25(3):1302—1314. http://europepmc.org/abstract/MED/32862570

Sada A, Yamashita TS, Glasgow AE, Habermann EB, et al. Comparison of benign and malignant insulinoma. Am J Surg. 2021;221(2):437-447. https://doi.org/10.1016/j.amjsurg.2020.08.003

Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc.;66(7):711-719. https://doi.org/10.1016/S0025-6196(12)62083-7

Yu J, Ping F, Zhang H, Li W, et al. Clinical management of malignant insulinoma: a single institution’s experience over three decades. BMC Endocr Disord. 2018;18(1):92. https://doi.org/10.1186/s12902-018-0321-8

Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675-686. https://doi.org/10.1097/MPA.0000000000000110

Tobón-Ospina C, Castaño P, Gutiérrez-Restrepo J, Torres-Grajales JL, et al. Descripción de la experiencia en pacientes diagnosticados con insulinoma. Estudio multicéntrico en Medellín, Colombia. Iatreia. 2020;33(2):133-142. https://doi.org/10.17533/udea.iatreia.41

de Herder WW, Niederle B, Scoazec JY, Pauwels S, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84(3):183-188. https://doi.org/10.1159/000098010

Rayas MS, Salehi M. Non-Diabetic Hypoglycemia. En Feingold KR, Anawalt B, Blackman MR, et al. Endotext. South Dartmouth, MA, EEUU: MD Text.com; 2020. https://www.ncbi.nlm.nih.gov/books/NBK355894/

Hofland J, Falconi M, Christ E, Castaño JP, et al. European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. https://doi.org/10.1111/jne.13318

Hirshberg B, Cochran C, Skarulis MC, Libutti SK, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104(2):264-272. https://doi.org/10.1002/cncr.21179

Dobrindt EM, Mogl M, Goretzki PE, Pratschke J, Dukaczewska AK. Insulinoma in pregnancy (a case presentation and systematic review of the literature). Rare Tumors. 2021;13:2036361320986647. https://doi.org/10.1177/2036361320986647

Ito T, Masui T, Komoto I, Doi R, et al. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol. 2021;56(11):1033-1044. https://doi.org/10.1007/s00535-021-01827-7

Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19(6):829-837. https://doi.org/10.3748/wjg.v19.i6.829

Martens P, Tits J. Approach to the patient with spontaneous hypoglycemia. Eur J Intern Med. 2014;25(5):415-421. https://doi.org/10.1016/j.ejim.2014.02.011

Kinova MK. Diagnostics and treatment of insulinoma. Neoplasma. 2015;62(05):692-704. https://doi.org/10.4149/neo_2015_083

Service FJ. Hypoglycemic disorders. N Engl J Med. 1995;332(17):1144-1452. https://doi.org/10.1056/NEJM199504273321707

Ueda K, Kawabe K, Lee L, Tachibana Y, et al. Diagnostic performance of 48-hour fasting test and insulin surrogates in patients with suspected insulinoma. Pancreas. 2017;46(4): 476-481. https://doi.org/10.1097/MPA.0000000000000772

O’Riordain DS, O’Brien T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg. 1994;18(4):488-493. https://doi.org/10.1007/BF00353743

Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol. 2003;14(4):293-301. https://doi.org/10.1385/EP:14:4:293

Jensen RT, Cadiot G, Brandi ML, de Herder WW, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98-119. https://doi.org/10.1159/000335591

Amin MB, Greene FL, Edge SB, Compton CC, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. https://doi.org/10.3322/caac.21388

Rindi G. The ENETS guidelines: the new TNM classification system. Tumori. 2010;96(5):806-809. https://doi.org/10.1177/030089161009600532

Christ E, Antwi K, Fani M, Wild D. Innovative imaging of insulinoma: the end of sampling? A review. Endocr Relat Cancer. 2020;27(4):R79-R92. https://doi.org/10.1530/ERC-19-0476

De León-Crutchlow DD, Stanley CA, editores. Congenital hyperinsulinism: a practical guide to diagnosis and management (contemporary endocrinology). 1.ª ed. Humana; 2019. 308 p. https://doi.org/10.1007/978-3-030-02961-6

Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and therapy management of pancreatic neuroendocrine tumors. Diagnostics (Basel). 2020;10(12):1059. https://doi.org/10.3390/diagnostics10121059

Chang L, Bi X, Li S, Tong Q, et al. The comparison of three different molecular imaging methods in localization and grading of insulinoma. Front Endocrinol. 2023;14:1163176. https://doi.org/10.3389/fendo.2023.1163176

Nockel P, Babic B, Millo C, Herscovitch P, et al. Localization of insulinoma using 68Ga-DOTATATE PET/CT scan. J Clin Endocrinol Metab. 2017;102(1):195-199. https://doi.org/10.1210/jc.2016-3445

Vahidfar N, Farzanehfar S, Abbasi M, Mirzaei S, et al. Diagnostic value of radiolabelled somatostatin analogues for neuroendocrine tumour diagnosis: the benefits and drawbacks of [(64)Cu]Cu-DOTA-TOC. Cancers (Basel). 2022;14(8):1914. https://doi.org/10.3390/cancers14081914

Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas-predominance of receptor subtype 4. Endocr Pathol. 2007;18(2):79-85. https://doi.org/10.1007/s12022-007-0014-8

Peltola E, Vesterinen T, Leijon H, Hannula P, et al. Immunohistochemical somatostatin receptor expression in insulinomas. APMIS. 2023;131(4):152-160. https://doi.org/10.1111/apm.13297

Maggio I, Mollica V, Brighi N, Lamberti G, et al. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest. 2020;43(2):139-148. https://doi.org/10.1007/s40618-019-01091-w

Refardt J, Hofland J, Kwadwo A, Nicolas GP, et al. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Rev Endocr Metab Disord. 2021;22(3):581-594. https://doi.org/10.1007/s11154-020-09552-x

Eusebi LH, Thorburn D, Toumpanakis C, Frazzoni L, et al. Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors. Endosc Int Open. 2019;7(11):E1393-E1399. https://doi.org/10.1055/a-0967-4684

Zandee WT, Brabander T, Blaževi? A, Kam BLR, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104(4):1336-1344. https://doi.org/10.1210/jc.2018-01991

Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf). 2018;88(5):615-624. https://doi.org/10.1111/cen.13528

Belfiori G, Wiese D, Partelli S, Wächter S, et al. Minimally invasive versus open treatment for benign sporadic insulinoma comparison of short-term and long-term outcomes. World J Surg. 2018;42(10):3223-3230. https://doi.org/10.1007/s00268-018-4628-4

Fierro LF, Sánchez JO, Tapiero M, Flórez A, et al. Diabetes posterior a tratamiento no quirúrgico de un insulinoma maligno: reporte de caso y revisión literatura. Rev Colomb Cancerol. 2020;24(1):30-36. https://doi.org/10.35509/01239015.138

Keutgen XM, Nilubol N, Glanville J, Sadowski SM, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159(1):311-318. https://doi.org/10.1016/j.surg.2015.05.042

Ye H, Xu HL, Shen Q, Zheng Q, Chen P. Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors. J Surg Res. 2019;243:578-587. https://doi.org/10.1016/j.jss.2019.04.002

Mosquera-Klinger G, Carvajal JJ. Endoscopic ultrasound-guided ethanol ablation for the management of a symptomatic pancreatic insulinoma. Rev Esp Enferm Dig. 2021;113(1):48-51. https://doi.org/10.17235/reed.2020.7109/2020

D?bkowski K, Gajewska P, Walter K, Londzin-Olesik M, et al. Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review. Endokrynol Pol. 2017;68(4):472-479. https://doi.org/10.5603/EP.2017.0053

Marx M, Trosic-Ivanisevic T, Caillol F, Demartines N, et al. EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers. Gastrointest Endosc. 2022;95(6):1256-1263. https://doi.org/10.1016/j.gie.2021.11.045

El Sayed G, Frim L, Franklin J, McCrudden R, et al. Endoscopic ultrasound-guided ethanol and radiofrequency ablation of pancreatic insulinomas: a systematic literature review. Therap Adv Gastroenterol. 2021;14:175628482110421. https://doi.org/10.1177/17562848211042171

Kos-Kud?a B, Rosiek V, Borowska M, Bednarczuk T, Bet al. Pancreatic neuroendocrine neoplasms - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022;73(3):491-548. https://doi.org/10.5603/EP.a2022.0050

Orgera G, Krokidis M, Monfardini L, Bonomo G, et al. High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases. Cardiovasc Intervent Radiol. 2011;34(2):419-423. https://doi.org/10.1007/s00270-010-9884-0

Chen OT, Dojki FK, Weber SM, Hinshaw JL. Percutaneous microwave ablation of an insulinoma in a patient with refractory symptomatic hypoglycemia. J Gastrointest Surg. 2015;19(7):1378-1381. https://doi.org/10.1007/s11605-015-2831-2

Jayawickreme KP, Muthukuda DT, Kariyawasam C, Piyarisi L, Abeywickrama BA. A rare case of insulinoma presenting with deep vein thrombosis, successfully treated with minimally invasive procedures including microwave ablation. Endocrinol Diabetes Metab Case Rep. 2022;2022:21-0127. https://doi.org/10.1530/EDM-21-0127

Qin S, Liu Y, Ning H, Tao L, et al. EUS-guided lauromacrogol ablation of insulinomas: a novel treatment. Scand J Gastroenterol. 2018;53(5):616-620. https://doi.org/10.1080/00365521.2017.1402206

Papamichail M, Ali A, Pizanias M, Peddu P, et al. Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors. Korean J Hepatobiliary Pancreat Surg. 2016;20(3):116-120. https://doi.org/10.14701/kjhbps.2016.20.3.116

Ghorashi NS, Ghodasara N, Liddell RP. Percutaneous cryoablation of an insulinoma in a patient with symptomatic hypoglycemia refractory to bland microsphere embolization. Cardiovasc Intervent Radiol. 2022;45(4):530-532. https://doi.org/10.1007/s00270-021-03046-2

Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf). 2008;68(6):912-918. https://doi.org/10.1111/j.1365-2265.2007.03161.x

Aida A, Noto H. Diagnosis and treatment course of insulinoma presenting as hypoglycemia unawareness using a factory-calibrated continuous glucose monitoring system. Am J Case Rep. 2022;23:e936723. https://doi.org/10.12659/AJCR.936723

Yuan T, Liu S, Zhu C, Dong Y, et al. Continuous glucose monitoring in patients with insulinoma treated by endoscopic ultrasound-guided ethanol injection. Pancreas. 2021;50(2):183-188. https://doi.org/10.1097/MPA.0000000000001735

Lyerla RC, Bajaj A, Shrestha RT. Use of a continuous glucose monitor for preoperative monitoring and treatment of hypoglycemia in a case of pancreatic neuroendocrine tumor. AACE Clin Case Rep. 2019;5(4):e255-e258. https://doi.org/10.4158/ACCR-2018-0590

Sugawa T, Murakami T, Yabe D, Kashima R, et al. Hypoglycemia unawareness in insulinoma revealed with flash glucose monitoring systems. Intern Med. 2018;57(23):3407-3412. https://doi.org/10.2169/internalmedicine.1173-18

Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother. 2021;22(6):685-693. https://doi.org/10.1080/14656566.2020.1845651

Yasuda A, Seki T, Kitajima N, Baba T, et al. A case of insulinoma effectively treated with low-dose diazoxide. Clin Case Rep. 2020;8(10):1884-189. https://doi.org/10.1002/ccr3.3017

Shah MH, Goldner WS, Benson AB, Bergsland E, et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Jul 28;19(7):839-868. https://doi.org/10.6004/jnccn.2021.0032

Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin analogs in clinical practice: a review. Int J of Mol Sci. 2020;21(5):1682. https://doi.org/10.3390/ijms21051682

Baudin E, Caron P, Lombard-Bohas C, Tabarin A, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74(5-6):523-533. https://doi.org/10.1016/j.ando.2013.07.001

Gilliaux Q, Bertrand C, Hanon F, Donckier JE. Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues? Acta Chir Belg. 2022;122(2):136-139. https://doi.org/10.1080/00015458.2020.1765676

Husni H, Khan SA, Alghaieb B, Abusamaan MS, et al. Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature. Clin Case Rep. 2022;10(3):e05650. https://doi.org/10.1002/ccr3.5650

Bolanowski M, Ka?u?ny M, Witek P, Jawiarczyk-Przyby?owska A. Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord. 2022;23(3):601-620. https://doi.org/10.1007/s11154-022-09710-3

Matej A, Bujwid H, Wro?ski J. Glycemic control in patients with insulinoma. Hormones (Athens). 2016;15(4):489-499. https://doi.org/10.14310/horm.2002.1706

Yao JC, Shah MH, Ito T, Bohas CL, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523. https://doi.org/10.1056/NEJMoa1009290

Bernard V, Lombard-Bohas C, Taquet M-C, Caroli-Bosc F-X, et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol. 2013;168(5):665-674. https://doi.org/10.1530/EJE-12-1101

Veltroni A, Cosaro E, Spada F, Fazio N, et al. Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur J Endocrinol. 2020;182(4):439-446. https://doi.org/10.1530/EJE-19-0989

Magalhães D, Sampaio IL, Ferreira G, Bogalho P, et al. Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. J Endocrinol Invest. 2019;42(3):249-460. https://doi.org/10.1007/s40618-018-0911-3

Strosberg JR, Fine RL, Choi J, Nasir A, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268-275. https://doi.org/10.1002/cncr.25425

Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023;41(7):1359-1369. https://doi.org/10.1200/JCO.22.01013

Chan JA, Stuart K, Earle CC, Clark JW, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012;30(24):2963-2968. https://doi.org/10.1200/JCO.2011.40.3147

Claringbold PG, Turner JH. Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-Capecitabine-Temozolomide radiopeptide chemotherapy. Neuroendocrinology. 2016;103(5):432-439. https://doi.org/10.1159/000434723

Raymond E, Dahan L, Raoul J-L, Bang Y-J, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513. https://doi.org/10.1056/NEJMoa1003825

Pozzari M, Maisonneuve P, Spada F, Berruti A, Amoroso V, Cella CA, et al. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. Cancer Treat Rev. 2018;71:39-46. https://doi.org/10.1016/j.ctrv.2018.10.008

González Clavijo AM, Fierro Maya LF, Vallejo González S, López Salazar A, et al. Embolización de metástasis hepáticas en insulinoma maligno: de la hipoglicemia a la hiperglicemia. Rev Colomb Cancerol. 2017;21(3):179-183. https://doi.org/10.1016/j.rccan.2016.07.003

Pavel M, Baudin E, Couvelard A, Krenning E, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-176. https://doi.org/10.1159/000335597

Linch F, Thompson S, Fleming C, Vella A, Andrews J. Hepatic artery embolization for palliation of symptomatic hypoglycemia in patients with hepatic insulinoma metastases. J Endocr Soc. 2021;5(12):bvab149. https://doi.org/10.1210/jendso/bvab149

Chandra P, Yarandi SS, Khazai N, Jacobs S, Umpierrez GE. Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. Am J Med Sci. 2010;340(5):414-417. https://doi.org/10.1097/MAJ.0b013e3181ee7be2

Llorente R, Venkat S, Doshi M, Portlance L. Y-90 selective internal radiation therapy to control hypoglycemia caused by liver metastases from malignant insulinoma. Int J Case Reports Ther Stud. 2019;1:002. https://doi.org/10.24966/CRTS-310X/100002

Peltola E, Hannula P, Huhtala H, Metso S, et al. Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol. 2021;185(4):577-586. https://doi.org/10.24966/CRTS-310X/100002

Crippa S, Zerbi A, Boninsegna L, Capitanio V, et al. Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg. 2012;147(3):261-266. https://doi.org/10.1001/archsurg.2011.1843

Câmara-de-Souza AB, Toyoshima MTK, Giannella ML, Freire DS, et al. Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors. Pancreatol. 2018;18(3):298-303. https://doi.org/10.1016/j.pan.2018.01.009

Sada A, Glasgow AE, Vella A, Thompson GB, et al. Malignant insulinoma: a rare form of neuroendocrine tumor. World J Surg. 2020;44(7):2288-2294. https://doi.org/10.1007/s00268-020-05445-x

Rindi G, Mete O, Uccella S, Basturk O, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115-154. https://doi.org/10.1007/s12022-022-09708-2

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

Dimensions


PlumX


Downloads

Download data is not yet available.